Literature DB >> 11506487

Liver metastases from colorectal cancer: regional intra-arterial treatment following failure of systemic chemotherapy.

A Cyjon1, M Neuman-Levin, E Rakowsky, F Greif, A Belinky, E Atar, R Hardoff, B Brenner, A Sulkes.   

Abstract

This study was designed to determine response rate, survival and toxicity associated with combination chemotherapy delivered intra-arterially to liver in patients with hepatic metastases of colorectal origin refractory to standard systemic treatment. A total of 28 patients who failed prior systemic treatment with fluoropyrimidines received a median of 5 cycles of intra-arterial treatment consisting of 5-fluorouracil 700 mg/m(2)/d, leucovorin 120 mg/m(2)/d, and cisplatin 20 mg/m(2)/d for 5 consecutive days. Cycles were repeated at intervals of 5-6 weeks. A major response was achieved in 48% of patients: complete response in 8% and partial response in 40%. The median duration of response was 11.5 months. Median survival was 12 months at a median follow up of 12 months. On multivariate analysis, the only variables with a significant impact on survival were response to treatment and performance status. Toxicity was moderate: grades III-IV neutropenia occurred in 29% of patients. Most of the patients complained of fatigue lasting for a few days following each cycle. There were no cases of hepatobiliary toxicity. These findings indicate that regional intra-arterial treatment should be considered in selected patients with predominantly liver disease following failure of standard treatment. Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11506487      PMCID: PMC2364094          DOI: 10.1054/bjoc.2001.1972

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  16 in total

1.  Phase II trial of irinotecan in patients with metastatic colorectal carcinoma.

Authors:  H C Pitot; D B Wender; M J O'Connell; G Schroeder; R M Goldberg; J Rubin; J A Mailliard; J A Knost; C Ghosh; R J Kirschling; R Levitt; H E Windschitl
Journal:  J Clin Oncol       Date:  1997-08       Impact factor: 44.544

2.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.

Authors:  J Y Douillard; D Cunningham; A D Roth; M Navarro; R D James; P Karasek; P Jandik; T Iveson; J Carmichael; M Alakl; G Gruia; L Awad; P Rougier
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

3.  A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases.

Authors:  A E Chang; P D Schneider; P H Sugarbaker; C Simpson; M Culnane; S M Steinberg
Journal:  Ann Surg       Date:  1987-12       Impact factor: 12.969

Review 4.  Clinical pharmacology of hepatic arterial chemotherapy.

Authors:  W D Ensminger; J W Gyves
Journal:  Semin Oncol       Date:  1983-06       Impact factor: 4.929

5.  Cancer statistics, 1998.

Authors:  S H Landis; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  1998 Jan-Feb       Impact factor: 508.702

6.  cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice.

Authors:  F M Schabel; M W Trader; W R Laster; T H Corbett; D P Griswold
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

7.  Pilot trial of prolonged continuous-infusion 5-fluorouracil and weekly cisplatin in advanced colorectal cancer.

Authors:  J E Cantrell; R D Hart; R F Taylor; J H Harvey
Journal:  Cancer Treat Rep       Date:  1987-06

8.  Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial.

Authors:  N Kemeny; J Daly; B Reichman; N Geller; J Botet; P Oderman
Journal:  Ann Intern Med       Date:  1987-10       Impact factor: 25.391

9.  Treatment of patients with advanced colorectal cancer with cisplatin, 5-fluorouracil, and leucovorin.

Authors:  W Scheithauer; H Rosen; R Schiessel; J Schüller; M Karall; F Ernst; C Sebesta; G Kornek; E Hentschel; A Marczell
Journal:  Cancer       Date:  1991-03-01       Impact factor: 6.860

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.